A reflection on how we define, determine and interpret the finding of lupus anticoagulant

Reumatol Clin (Engl Ed). 2018 Mar-Apr;14(2):120-122. doi: 10.1016/j.reuma.2017.04.013. Epub 2017 Jun 7.

[Article in English, Spanish]

Authors

Lara Valor¹, Diana Hernández-Flórez², Julia Martínez-Barrio², Francisco Javier López Longo²

Affiliations

¹ Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Biomédica, Hospital Gregorio Marañón, Madrid, España. Electronic address: lvalor.hgugm@salud.madrid.org.
² Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Biomédica, Hospital Gregorio Marañón, Madrid, España.

PMID: 28599869
DOI: 10.1016/j.reuma.2017.04.013

No abstract available

Publication types

Letter

MeSH terms

Antiphospholipid Syndrome / blood
Antiphospholipid Syndrome / complications
Antiphospholipid Syndrome / diagnosis*
Asymptomatic Diseases
Biomarkers / blood
Female
Humans
Lupus Coagulation Inhibitor / blood*
Lupus Erythematosus, Systemic / blood
Lupus Erythematosus, Systemic / complications
Lupus Erythematosus, Systemic / diagnosis*
Pregnancy
Pregnancy Complications / blood
Pregnancy Complications / etiology
Pregnancy Complications / prevention & control*
Risk Assessment
Risk Factors
Thrombosis / blood
Thrombosis / etiology
Thrombosis / prevention & control*

Substances

Biomarkers
Lupus Coagulation Inhibitor